Table 5 Clinical characteristics associated with EQ-5D and EQ-VAS score of patients with HIV/AIDS, TASH, Ethiopia, 2019 (n = 511)

CD4 cells/mm³

 > 500

1 [0.94–1]

90 [82–99.75]

[350–500]

0.94 [0.88–1]

85 [70.25–90]

[200–350]

0.94 [0.86–0.97]

77.5 [65–85]

[100–200]

0.88 [0.76–0.95]

70 [60–85]

 < 100

0.88 [0.66–0.96]

60 [50–83.75]

WHO clinical stage at diagnosis

I

0.94 [0.85–0.97]

85 [72.5–90]

II

0.96 [0.87–1]

85 [70–95]

III

0.96 [0.89–1]

82.5 [70–95]

IV

0.94 [0.86–1]

80 [65–90]

Viral load

 < 50 copies/ml

0.95 [0.88–1]

85 [70–95]

51–1000 copies/ml

0.94 [0.88–1]

82.5 [70–95]

 > 1000 copies/ml

0.88 [0.7–0.98]

70 [60–80]

Type of medicine

AZT/3TC/EFV

0.97 [0.94–1]

82.5 [70–91.75]

AZT/3TC/NVP

0.96 [0.88–1]

85 [71.25–90]

TDF/3TC/EFV

0.96 [0.88–1]

85 [70–95]

TDF/3TC/NVP

0.94 [0.89–1]

85 [75–95]

ABC + 3TC + EFV

0.88 [0.82–0.96]

70 [60–80]

TDF + 3TC + ATV/r

0.82 [0.77–0.97]

70 [51.25–85]

Others**

0.94 [0.86–1]

80 [65–90]

Number of medicine

1

0.96 [0.9–1]

90 [70–95]

2

0.94 [0.85–0.97]

80 [70–90]

3

0.94 [0.86–1]

80 [65–90]

4

0.91 [0.83–0.97]

75 [60–90]

 > 4

0.89 [0.76–0.97]

70 [50–80]

Duration of treatment

 < 1 year

0.96 [0.94–0.96]

85 [72.5–90]

1–5 years

0.92 [0.86–0.97]

80 [66.25–90]

 > 5 years

0.96 [0.88–1]

82.5 [70–95]

Adherence

Good

0.95 [0.88–1]

80 [70–90]

Fair

0.93 [0.84–1]

72.5 [56–93.75]

Poor

0.89 [0.7–1]

70 [60–90]

History of treatment failure

Yes

0.92 [0.83–0.97]

70 [60–85]

No

0.96 [0.88–1]

85 [70–95]

Comorbidities

No

0.96 [0.88–1]

85 [70–95]

OIs

0.92 [0.84–0.97]

70 [55–90]

Non-OIs

0.92 [0.8–0.97]

80 [65–90]